Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus + Genotype 1 Infected Subjects.
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Dasabuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Abbott Laboratories
- 26 Apr 2009 Pharmacokinetic results reported at The International Liver Congress 2009.
- 27 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Feb 2009 Planned number of patients changed from 116 to 133 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History